上美股份(02145.HK)盈喜:預計2024年集團利潤增加62.4%至75.4%
格隆匯3月3日丨上美股份(02145.HK)發佈公告,集團預計(i)截至2024年12月31日止年度的收入介乎約人民幣67億元至人民幣69億元,較截至2023年12月31日止年度的收入約人民幣41.907億元增加約59.9%至64.7%;及(ii)2024年度的集團利潤介乎約人民幣7.50億元至人民幣8.10億元,較2023年度的集團利潤約人民幣4.617億元增加約62.4%至75.4%。
根據目前可得資料,收入及利潤增加主要由於集團科學抗衰護膚品牌韓束及中國嬰童功效護膚品牌newpage一頁的收入同比大幅增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.